Home › Trials › NCT05582161
Clinical trial Recruiting at 2 sites Phase 2 Interventional Ages 50 to 90

Evaluating the effects of DAOIB on dementia symptoms

Official title: Efficacy Biomarkers of DAOIB for Dementia

Run by Chang Gung Memorial Hospital · NCT05582161 · Data updated 2026-11-12

This study is testing if a new treatment called DAOIB can help improve symptoms in people with mild Alzheimer's disease or mild cognitive impairment over six months.

More Dementia trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages50 Years to 90 Years
SexAll
Enrollment123 (estimated)
SponsorChang Gung Memorial Hospital
Academic / other
Locations2 sites (Kaohsiung City and 1 other locations)
StatusRecruiting
StartedOctober 3, 2022
Main results expectedSeptember 2026
Study endsSeptember 2026
Registry record updatedMarch 19, 2026
Trial IDNCT05582161 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with a clinical diagnosis of Alzheimer's disease or mild cognitive impairment, with an MMSE score between 10-26 and a CDR score of 1 or 0.5.

Probably not a fit

Patients with severe cognitive impairment, major depressive disorder, or other significant physical illnesses may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label clinical trial aims to assess the efficacy of DAOIB in patients diagnosed with amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD) over a 24-week period. Participants will undergo evaluations at baseline, 8 weeks, 16 weeks, and at the end of the study, with blood samples taken every 8 weeks to measure NMDA and oxidative stress-related biomarkers. The study hypothesizes that these biomarkers can predict the treatment's effectiveness in this patient population.

Why it matters

Potential benefit: If successful, this study could provide a new therapeutic option for patients with aMCI or mild AD, potentially improving their cognitive function.

How similar studies have gone: While the specific approach of using DAOIB in this context may be novel, similar studies targeting biomarkers in dementia have shown promise in the past.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
* MMSE between 10-26
* CDR 1 or 0.5

Exclusion Criteria:

* Hachinski Ischemic Score \> 4
* Substance abuse/dependence
* Parkinson disease, epilepsy, dementia with psychotic features
* Major depressive disorder
* Major physical illnesses
* Severe visual or hearing impairment

Where it's running

  • Chang Gung Memorial Hospital
    Kaohsiung City, Taiwan     Recruiting
  • China Medical University Hospital
    Taichung, Taiwan     Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Dementia 1271Chang Gung Memorial Hospital 95
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.